Nos publications

Gelucire 48/16® for Type-IV Lipid Based Formulations and Their In Vitro In Vivo Performance Evaluation

  • Poster

AAPS PharmSci360 – San Antonion (USA)  - nov 2019

Agnivesh Shrivastava, Ketkee Deshmukh, Sunil Bambarkar, Nabil Farah, Kavita Singh

Télécharger (.pdf - 898.26 Ko)

Bioavailable Curcumin – A Type 4 Lipid Based Drug Delivery System Using Gelucire®48/16 As Solid Solubilizer

  • Poster

CRS Annual Meeting – New York (USA)  - jui 2018

Ketkee Deshmukh, Sharda Gurram, Sunil Bambarkar, Vincent Jannin, Nabil Farah, Kavita Singh

Télécharger (.pdf - 5.42 Mo)

The Gelucire® family

  • Whitepaper

Pharma Excipients  - 2018

Gattefossé

Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity

  • Scientific publication

International Journal of Pharmaceutics, Volume 495, Issue 1, Pages 385-392 - nov 2015

Vincent Jannin, Stéphanie Chevrier, Matthieu Michenaud, Camille Dumont, Silvia Belotti, Yann Chavant, Fédéric Demarne.

This article describes the work undertaken in Gattefossé R&D labs (St Priest) to develop lipid formulations for low to medium lipophilicity API: piroxicam, nifedipine and curcumin and evaluate the effect of in-vitro digestion on the solubilizing capacity of the formulations.

Formulation of a self-emulsifying lipid formulation of curcumin

  • Poster

AAPS Annual Meeting & Exposition – San Diego (USA)  - 2014

Vincent Jannin, Camille Dumont, Hamza Benhaddou, Stéphanie Chevrier, Yann Chavant, Christophe Voutsinas, Frédéric Demarne

Télécharger (.pdf - 355.83 Ko)

Characterization of a new self-emulsifying excipient to expand formulation options for poorly soluble drugs: Gelucire® 48/16

  • Poster

AAPS Annual Meeting & Exposition – Chicago (USA)  - oct 2012

V. JANNIN, M. DI CUIA, S. CHEVRIER, A. FAURE, Y. CHAVANT, C. VOUTSINAS, F. DEMARNE

Télécharger (.pdf - 379.66 Ko)